Key Takeaways & Executive Findings
- •• Copper-containing calcium sulfate bone cement (Cu-CS) was successfully prepared with varying copper content (0.1%-2.5%). • Cu-CS cements exhibited improved compressive strength compared to pure calcium sulfate, with 2.5%Cu-CS showing the highest strength. • Cu-CS cements released copper ions in a sustained manner, with release concentration proportional to copper content. • In a rat tibial defect model, 0.5%Cu-CS significantly enhanced angiogenesis compared to control and blank groups, as evidenced by Micro-CT and CD31 staining.
Abstract
BACKGROUND: Calcium sulfate has been widely used as a bone graft for the treatment of alveolar bone loss, endodontic lesions, and periodontal disease. Copper plays an important role in various biological processes, including angiogenesis and cell migration. OBJECTIVE: To prepare copper-containing calcium sulfate bone cement and characterize its physicochemical properties and angiogenesis. METHODS: (1) Calcium sulfate hemihydrate was used as the solid phase and copper sulfate pentahydrate solutions of varying concentrations were used as the liquid phase. The solid and liquid phases were mixed at a ratio of 1.7 g/1 mL. The mass ratios of copper sulfate pentahydrate to calcium sulfate hemihydrate were 0.1%, 0.5%, 1%, and 2.5%, respectively. The prepared copper-containing calcium sulfate bone cements were designated 0.1%Cu-CS, 0.5%Cu-CS, 1%Cu-CS, and 2.5%Cu-CS, respectively. Pure calcium sulfate bone cement was also prepared. The micromorphology, compressive strength, and copper and calcium ion release in the in vitro degradation solution of the five cements were characterized. (2) Thirty SD rats selected and a single cortical bone defect model with a diameter of 3 mm and a length of 5 mm was established on the left tibia. These models were randomly divided into three groups: a blank group (n=10) received no intervention; a control group (n=10) received calcium sulfate bone cement implantation; an experimental group (n=10) received 0.5%Cu-CS bone cement implantation. At 6 weeks postoperatively, vascular Microfil perfusion followed by Micro-CT scanning was performed to observe angiogenesis at the tibial defect site, and CD31 immunohistochemical staining was used to observe angiogenesis. RESULTS AND CONCLUSION: (1) Scanning electron microscopy showed rod-like calcium sulfate crystals on the surface of calcium sulfate bone cement, while plate-like gypsum crystals were present on the surface of copper-containing calcium sulfate bone cement. With increasing copper sulfate pentahydrate content, the number of plate-like gypsum crystals increased. The compressive strength of 0.5%Cu-CS and 1%Cu-CS cements was higher than that of calcium sulfate cement and 0.1%Cu-CS cement (P < 0.05), and the compressive strength of 2.5%Cu-CS cement was higher than that of 0.5%Cu-CS and 1%Cu-CS cements (P < 0.05). After immersion in simulated body fluid for 6 weeks, calcium sulfate cement showed the highest calcium ion release concentration, while 2.5%Cu-CS cement showed the lowest. No copper ion release was detected from calcium sulfate cement; among copper-containing cements, 2.5%Cu-CS had the highest copper ion release, and 0.1%Cu-CS had the lowest. (2) Micro-CT scanning showed that the blank group had the least new blood vessel formation at the bone defect, while the experimental group had the most. CD31 immunohistochemical staining showed that the blank and control groups only exhibited punctate or linear new vascular structures, whereas the experimental group showed abundant and dense vascular formation. (3) These results indicate that copper-containing calcium sulfate bone cement possesses good mechanical properties and sustained copper ion release, and can promote angiogenesis.
1. Introduction
Calcium sulfate has been used clinically for over 100 years [1], and it possesses good biocompatibility and complete absorbability [2]. As a bone graft, calcium sulfate is used in the treatment of alveolar bone loss, endodontic lesions, and periodontal disease [3-4]. Studies have reported that calcium sulfate can serve as a carrier for antibiotics such as amoxicillin and moxifloxacin in the treatment of chronic osteomyelitis [5-7], and as an antibiotic carrier for prosthetic joint infections. Furthermore, calcium sulfate has some osteoregenerative effects; SHAH et al. [8] used calcium sulfate in surgeries for upper limb nonunion and malunion, and CEN et al. [9] found that poly-L-lactic acid/calcium sulfate composites exhibit significant immunomodulatory effects on bone. ZHANG et al. [10] showed that phosphosilicate bioactive glass and calcium sulfate composites can promote the proliferation and angiogenesis of human umbilical vein endothelial cells, indicating that calcium sulfate has certain pro-angiogenic effects.
Metal ions have advantages such as low cost, high stability, and clinical safety, making them attractive as bioactive factors for bioceramic materials [11]. Copper is an essential micronutrient for normal development in eukaryotes and plays key roles in many cellular and physiological activities, including enzyme activity, oxygen transport, and cell signaling [12]. FINNEY et al. [13] reported that copper is essential for angiogenesis and plays a critical role in skin regeneration and angiogenesis. BARRALET et al. [14] showed that low-dose copper-loaded calcium phosphate scaffolds can promote angiogenesis and wound healing. KONG et al. [15] confirmed that the synergistic effect of copper and silicon ions in copper-containing calcium silicate promotes angiogenesis. LI et al. [16] prepared a dual-network composite gel with self-regulating copper ion release to promote wound healing. LI et al. [17] studied the immunomodulatory and pro-angiogenic effects of copper-containing titanium alloy (Ti6Al4V-1.5Cu) and found that it promotes angiogenesis by releasing copper ions and inhibiting inflammation. In bioactive nanoparticles, copper regulates various cytokines and growth factors involved in different stages of wound healing [18]; additionally, copper has antibacterial activity and synergistic effects in promoting wound healing [19-20]. Therefore, the authors hypothesized that the addition of copper ions to calcium sulfate may have a synergistic biological effect, improving the properties of this bone substitute. In this study, we prepared copper-containing calcium sulfate cement and analyzed its in vivo pro-angiogenic effects.
Loading authentic research manuscript (Pages 1–5)...
Huang Lei, Lan Tian, Zeng Hui (2026). Physicochemical properties and angiogenesis-promoting effects of copper-containing calcium sulfate bone cement. Chinese Journal of Tissue Engineering Research. https://doi.org/10.12307/2026.21458
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is copper-containing calcium sulfate bone cement?
Copper-containing calcium sulfate bone cement is a composite material made by mixing calcium sulfate hemihydrate with copper sulfate pentahydrate solutions. It combines the osteoconductive properties of calcium sulfate with the pro-angiogenic effects of copper ions, aiming to enhance bone repair.
How does copper promote angiogenesis in bone repair?
Copper ions are known to stimulate the expression of angiogenic factors such as vascular endothelial growth factor (VEGF), promoting endothelial cell proliferation and migration, which leads to new blood vessel formation. This is crucial for nutrient supply and waste removal during bone regeneration.
What are the key findings of this study?
The study demonstrated that copper-containing calcium sulfate bone cement with 0.5% copper content significantly enhanced angiogenesis in a rat tibial defect model compared to pure calcium sulfate and no treatment. The material also showed good mechanical properties and sustained copper ion release.
What is the optimal copper concentration in the cement?
The study found that 0.5%Cu-CS (0.5% copper sulfate pentahydrate by mass) provided a balance between mechanical strength and pro-angiogenic effects, making it a promising composition for further clinical applications.
What are the potential clinical applications of this material?
This material could be used as a bone graft substitute in orthopedic and dental surgeries, particularly in cases where enhanced vascularization is needed, such as large bone defects, nonunions, and periodontal regeneration.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.